1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


  
    













































































































































    The Added Prognostic Value of Preoperative Dynamic Contrast-Enhanced MRI Histogram Analysis in Patients with Glioblastoma: Analysis of Overall and Progression-Free Survival | American Journal of Neuroradiology  
    



















    































    
  
  




    
    

  

      


    

      

  
  
  

    

  

    

  

                
    

      

  

    

  
      
  
  

    


Advertisement



  



  


  
  



  



    

  


  


  


  
  
  
  
  
  

  	      


    
      

    
  
    
        
    

  

    
                        

  

                
    

      

	  

		
		

			

			  

  
      
  
  

    

  
  
      
Research ArticleADULT BRAIN

  
      

  
      
The Added Prognostic Value of Preoperative Dynamic Contrast-Enhanced MRI Histogram Analysis in Patients with Glioblastoma: Analysis of Overall and Progression-Free Survival
  
    	
Y.S. Choi, D.W. Kim, S.-K. Lee, J.H. Chang, S.-G. Kang, E.H. Kim, S.H. Kim, T.H. Rim and S.S. Ahn

  
    	
American Journal of Neuroradiology December 2015,  36 (12) 2235-2241; DOI: https://doi.org/10.3174/ajnr.A4449 

  
  
  



  


  
  



			

		

	
	
 	
	  
  

		
		

			

			  

  
      
  
  

    
  


  
  



  
      
  
  

    

  

    

  
      
  
  

    
REFERENCES
  1. 1.↵
    1. 

    2. Van Meir  EG, 
    3. Hadjipanayis  CG, 
    4. Norden  AD, et al
    . Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010;60:166–93 doi:10.3322/caac.20069 pmid:20445000
    CrossRefPubMedWeb of Science
  2. 2.↵
    1. 

    2. Zikou  AK, 
    3. Alexiou  GA, 
    4. Kosta  P, et al
    . Diffusion tensor and dynamic susceptibility contrast MRI in glioblastoma. Clin Neurol Neurosurg 2012;114:607–12 doi:10.1016/j.clineuro.2011.12.022 pmid:22266399
    CrossRefPubMed
  3. 3.↵
    1. 

    2. Liu  Y, 
    3. Shete  S, 
    4. Etzel  CJ, et al
    . Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival. J Clin Oncol 2010;28:2467–74 doi:10.1200/JCO.2009.26.6213 pmid:20368557
    Abstract/FREE Full Text
  4. 4.↵
    1. 

    2. Stark  AM, 
    3. Stepper  W, 
    4. Mehdorn  HM
    . Outcome evaluation in glioblastoma patients using different ranking scores: KPS, GOS, mRS and MRC. Eur J Cancer Care (Engl) 2010;19:39–44 doi:10.1111/ecc.2010.19.issue-1 pmid:19912295
    CrossRefPubMedWeb of Science
  5. 5.↵
    1. 

    2. Lacroix  M, 
    3. Abi-Said  D, 
    4. Fourney  DR, et al
    . A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95:190–98 doi:10.3171/jns.2001.95.2.0190 pmid:11780887
    CrossRefPubMedWeb of Science
  6. 6.↵
    1. 

    2. Mellinghoff  IK, 
    3. Wang  MY, 
    4. Vivanco  I, et al
    . Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012–24 doi:10.1056/NEJMoa051918 pmid:16282176
    CrossRefPubMedWeb of Science
  7. 7.↵
    1. 

    2. Hegi  ME, 
    3. Diserens  AC, 
    4. Gorlia  T, et al
    . MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997–1003 doi:10.1056/NEJMoa043331 pmid:15758010
    CrossRefPubMedWeb of Science
  8. 8.↵
    1. 

    2. Simmons  ML, 
    3. Lamborn  KR, 
    4. Takahashi  M, et al
    . Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 2001;61:1122–28 pmid:11221842
    Abstract/FREE Full Text
  9. 9.↵
    1. 

    2. Shiraishi  S, 
    3. Tada  K, 
    4. Nakamura  H, et al
    . Influence of p53 mutations on prognosis of patients with glioblastoma. Cancer 2002;95:249–57 doi:10.1002/cncr.10677 pmid:12124823
    CrossRefPubMedWeb of Science
  10. 10.↵
    1. 

    2. Shinojima  N, 
    3. Tada  K, 
    4. Shiraishi  S, et al
    . Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003;63:6962–70 pmid:14583498
    Abstract/FREE Full Text
  11. 11.↵
    1. 

    2. Pope  WB, 
    3. Sayre  J, 
    4. Perlina  A, et al
    . MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 2005;26:2466–74 pmid:16286386
    Abstract/FREE Full Text
  12. 12.↵
    1. 

    2. Chaichana  KL, 
    3. Kosztowski  T, 
    4. Niranjan  A, et al
    . Prognostic significance of contrast-enhancing anaplastic astrocytomas in adults. J Neurosurg 2010;113:286–92 doi:10.3171/2010.2.JNS091010 pmid:20302391
    CrossRefPubMedWeb of Science
  13. 13.↵
    1. 

    2. Tynninen  O, 
    3. Aronen  HJ, 
    4. Ruhala  M, et al
    . MRI enhancement and microvascular density in gliomas: correlation with tumor cell proliferation. Invest Radiol 1999;34:427 doi:10.1097/00004424-199906000-00007 pmid:10353036
    CrossRefPubMed
  14. 14.↵
    1. 

    2. Hammoud  MA, 
    3. Sawaya  R, 
    4. Shi  W, et al
    . Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol 1996;27:65–73 doi:10.1007/BF00146086 pmid:8699228
    CrossRefPubMed
  15. 15.↵
    1. 

    2. Higano  S, 
    3. Yun  X, 
    4. Kumabe  T, et al
    . Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 2006;241:839–46 doi:10.1148/radiol.2413051276 pmid:17032910
    CrossRefPubMedWeb of Science
  16. 16.↵
    1. 

    2. Oh  J, 
    3. Henry  RG, 
    4. Pirzkall  A, et al
    . Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging 2004;19:546–54 doi:10.1002/jmri.20039 pmid:15112303
    CrossRefPubMed
  17. 17.↵
    1. 

    2. Murakami  R, 
    3. Sugahara  T, 
    4. Nakamura  H, et al
    . Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging. Radiology 2007;243:493–99 doi:10.1148/radiol.2432060450 pmid:17356177
    CrossRefPubMedWeb of Science
  18. 18.↵
    1. 

    2. Law  M, 
    3. Young  RJ, 
    4. Babb  JS, et al
    . Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247:490–98 doi:10.1148/radiol.2472070898 pmid:18349315
    CrossRefPubMedWeb of Science
  19. 19.↵
    1. 

    2. Pope  WB, 
    3. Lai  A, 
    4. Mehta  R, et al
    . Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol 2011;32:882–89 doi:10.3174/ajnr.A2385 pmid:21330401
    Abstract/FREE Full Text
  20. 20.↵
    1. 

    2. Boxerman  J, 
    3. Schmainda  K, 
    4. Weisskoff  R
    . Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 2006;27:859–67 pmid:16611779
    Abstract/FREE Full Text
  21. 21.↵
    1. 

    2. Paulson  ES, 
    3. Schmainda  KM
    . Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology 2008;249:601–13 doi:10.1148/radiol.2492071659 pmid:18780827
    CrossRefPubMedWeb of Science
  22. 22.↵
    1. 

    2. Hu  L, 
    3. Baxter  L, 
    4. Pinnaduwage  D, et al
    . Optimized preload leakage-correction methods to improve the diagnostic accuracy of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in posttreatment gliomas. AJNR Am J Neuroradiol 2010;31:40–48 doi:10.3174/ajnr.A1787 pmid:19749223
    Abstract/FREE Full Text
  23. 23.↵
    1. 

    2. Boxerman  J, 
    3. Prah  D, 
    4. Paulson  E, et al
    . The role of preload and leakage correction in gadolinium-based cerebral blood volume estimation determined by comparison with MION as a criterion standard. AJNR Am J Neuroradiol 2012;33:1081–87 doi:10.3174/ajnr.A2934 pmid:22322605
    Abstract/FREE Full Text
  24. 24.↵
    1. 

    2. Mills  SJ, 
    3. Patankar  TA, 
    4. Haroon  HA, et al
    . Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? AJNR Am J Neuroradiol 2006;27:853–58 pmid:16611778
    Abstract/FREE Full Text
  25. 25.↵
    1. 

    2. Nguyen  TB, 
    3. Cron  GO, 
    4. Mercier  JF, et al
    . Preoperative prognostic value of dynamic contrast-enhanced MRI-derived contrast transfer coefficient and plasma volume in patients with cerebral gliomas. AJNR Am J Neuroradiol 2015;36:63–69 doi:10.3174/ajnr.A4006 pmid:24948500
    Abstract/FREE Full Text
  26. 26.↵
    1. 

    2. Kim  YS, 
    3. Kim  SH, 
    4. Cho  J, et al
    . MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study. Int J Radiat Oncol Biol Phys 2012;84:661–67 doi:10.1016/j.ijrobp.2011.12.086 pmid:22414280
    CrossRefPubMed
  27. 27.↵
    1. 

    2. Wang  Y, 
    3. Li  S, 
    4. Chen  L, et al
    . Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. Neuro Oncol 2012;14:518–25 doi:10.1093/neuonc/nor232 pmid:22326863
    Abstract/FREE Full Text
  28. 28.↵
    1. 

    2. Parsons  DW, 
    3. Jones  S, 
    4. Zhang  X, et al
    . An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807–12 doi:10.1126/science.1164382 pmid:18772396
    Abstract/FREE Full Text
  29. 29.↵
    1. 

    2. Tofts  PS, 
    3. Brix  G, 
    4. Buckley  DL, et al
    . Estimating kinetic parameters from dynamic contrast-enhanced T (1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223–32 doi:10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S pmid:10508281
    CrossRefPubMedWeb of Science
  30. 30.↵
    1. 

    2. Haacke  EM, 
    3. Filleti  CL, 
    4. Gattu  R, et al
    . New algorithm for quantifying vascular changes in dynamic contrast-enhanced MRI independent of absolute T1 values. Magn Reson Med 2007;58:463–72 doi:10.1002/mrm.21358 pmid:17763352
    CrossRefPubMed
  31. 31.↵
    1. 

    2. Yun  TJ, 
    3. Park  CK, 
    4. Kim  TM, et al
    . Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging. Radiology 2015;274:830–40 doi:10.1148/radiol.14132632 pmid:25333475
    CrossRefPubMed
  32. 32.↵
    1. 

    2. Jung  SC, 
    3. Yeom  J, 
    4. Kim  JH, et al
    . Glioma: application of histogram analysis of pharmacokinetic parameters from T1-weighted dynamic contrast-enhanced MR imaging to tumor grading. AJNR Am J Neuroradiol 2014;35:1103–10 doi:10.3174/ajnr.A3825 pmid:24384119
    Abstract/FREE Full Text
  33. 33.↵
    1. 

    2. Alcaide-Leon  P, 
    3. Pareto  D, 
    4. Martinez-Saez  E, et al
    . Pixel-by-pixel comparison of volume transfer constant and estimates of cerebral blood volume from dynamic contrast-enhanced and dynamic susceptibility contrast-enhanced MR imaging in high-grade gliomas. AJNR Am J Neuroradiol 2015;36:871–76 doi:10.3174/ajnr.A4231 pmid:25634715
    Abstract/FREE Full Text
  34. 34.↵
    1. 

    2. Kang  HJ, 
    3. Eo  SH, 
    4. Kim  SC, et al
    . Increased number of metastatic lymph nodes in adenocarcinoma of the ampulla of Vater as a prognostic factor: a proposal of new nodal classification. Surgery 2014;155:74–84 doi:10.1016/j.surg.2013.08.004 pmid:24238122
    CrossRefPubMed
  35. 35.↵
    1. 

    2. Palumbo  A, 
    3. Avet-Loiseau  H, 
    4. Oliva  S, et al
    . Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol 2015;33:2863–69 JCO.2015.61.2267 pmid:26240224
    Abstract/FREE Full Text
  36. 36.↵
    1. 

    2. Newson  RB
    . Comparing the predictive powers of survival models using Harrell's C or Somers' D. Stata Journal 2010;10:339–58
    Web of Science
  37. 37.↵
    1. 

    2. Dolcetta-Capuzzo  A, 
    3. Villa  V, 
    4. Albarello  L, et al
    . Gastroenteric neuroendocrine neoplasms classification: comparison of prognostic models. Cancer 2013;119:36–44 doi:10.1002/cncr.27716 pmid:22744914
    CrossRefPubMed
  38. 38.↵
    1. 

    2. Venkatasubramanian  R, 
    3. Arenas  R, 
    4. Henson  M, et al
    . Mechanistic modelling of dynamic MRI data predicts that tumour heterogeneity decreases therapeutic response. Br J Cancer 2010;103:486–97 doi:10.1038/sj.bjc.6605773 pmid:20628390
    CrossRefPubMed
  39. 39.↵
    1. 

    2. Bonekamp  D, 
    3. Deike  K, 
    4. Wiestler  B, et al
    . Association of overall survival in patients with newly diagnosed glioblastoma with contrast-enhanced perfusion MRI: Comparison of intraindividually matched T1-and T2*-based bolus techniques. J Magn Reson Imaging 2015;42:87–96 doi:10.1002/jmri.24756 pmid:25244574
    CrossRefPubMed
  40. 40.↵
    1. 

    2. Awasthi  R, 
    3. Pandey  CM, 
    4. Sahoo  P, et al
    . Dynamic contrast-enhanced magnetic resonance imaging-derived kep as a potential biomarker of matrix metalloproteinase 9 expression in patients with glioblastoma multiforme: a pilot study. J Comput Assist Tomogr 2012;36:125–30 doi:10.1097/RCT.0b013e31823f6c59 pmid:22261782
    CrossRefPubMed
  41. 41.↵
    1. 

    2. Carmeliet  P, 
    3. Jain  RK
    . Angiogenesis in cancer and other diseases. Nature 2000;407:249–57 doi:10.1038/35025220 pmid:11001068
    CrossRefPubMedWeb of Science
  42. 42.↵
    1. 

    2. Law  M, 
    3. Oh  S, 
    4. Johnson  G, et al
    . Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery 2006;58:1099–107; discussion 1099–107 doi:10.1227/01.NEU.0000215944.81730.18 pmid:16723889
    CrossRefPubMedWeb of Science
  43. 43.↵
    1. 

    2. Caseiras  GB, 
    3. Chheang  S, 
    4. Babb  J, et al
    . Relative cerebral blood volume measurements of low-grade gliomas predict patient outcome in a multi-institution setting. Eur J Radiol 2010;73:215–20 doi:10.1016/j.ejrad.2008.11.005 pmid:19201123
    CrossRefPubMed
  44. 44.↵
    1. 

    2. Sugahara  T, 
    3. Korogi  Y, 
    4. Kochi  M, et al
    . Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 1998;171:1479–86 doi:10.2214/ajr.171.6.9843274 pmid:9843274
    CrossRefPubMedWeb of Science
  45. 45.↵
    1. 

    2. Law  M, 
    3. Yang  S, 
    4. Babb  JS, et al
    . Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 2004;25:746–55 pmid:15140713
    Abstract/FREE Full Text
  46. 46.↵
    1. 

    2. Ingrisch  M, 
    3. Dietrich  O, 
    4. Attenberger  UI, et al
    . Quantitative pulmonary perfusion magnetic resonance imaging: influence of temporal resolution and signal-to-noise ratio. Invest Radiol 2010;45:7–14 doi:10.1097/RLI.0b013e3181bc2d0c pmid:19996761
    CrossRefPubMed
  47. 47.↵
    1. 

    2. Ingrisch  M, 
    3. Sourbron  S
    . Tracer-kinetic modeling of dynamic contrast-enhanced MRI and CT: a primer. J Pharmacokinet Pharmacodyn 2013;40:281–300 doi:10.1007/s10928-013-9315-3 pmid:23563847
    CrossRefPubMed
  48. 48.↵
    1. 

    2. Sourbron  S
    . Technical aspects of MR perfusion. Eur J Radiol 2010;76:304–13 doi:10.1016/j.ejrad.2010.02.017 pmid:20363574
    CrossRefPubMed
  49. 49.↵
    1. 

    2. Ahearn  T, 
    3. Staff  R, 
    4. Redpath  T, et al
    . The effects of renal variation upon measurements of perfusion and leakage volume in breast tumours. Phys Med Boil 2004;49:2041–51 doi:10.1088/0031-9155/49/10/014 pmid:15214540
    CrossRefPubMed
  50. 50.↵
    1. 

    2. Dale  BM, 
    3. Jesberger  JA, 
    4. Lewin  JS, et al
    . Determining and optimizing the precision of quantitative measurements of perfusion from dynamic contrast enhanced MRI. J Magn Reson Imaging 2003;18:575–84 doi:10.1002/jmri.10399 pmid:14579401
    CrossRefPubMedWeb of Science
  51. 51.↵
    1. 

    2. Galbraith  SM, 
    3. Lodge  MA, 
    4. Taylor  NJ, et al
    . Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed 2002;15:132–42 doi:10.1002/nbm.731 pmid:11870909
    CrossRefPubMedWeb of Science
  


  
  



  




  


  
  



  
      
  
  

    
  


  
  



  
      
  
  

     Back to top  


  
  



			

		

		
		

			

			  

  
        
In this issue

    
  
  

    
  


  
  



  
      
  
  

    

  

    

  
      
  
  

    


Advertisement



  



  


  
  



  



  


  
  



  
      
  
  

    

	  
  

		

          

            

  
      
  
  

     Print  


  
  



  
      
  
  

     Download PDF  


  
  



  
      
  
  

    
 Email Article
  


  
  



  
      
  
  

    
 Citation Tools
  


  
  



          

        

        
        

          

            



  
      
  
  

    

  

    

  
      
  
  

    

  
  
  
  
      
The Added Prognostic Value of Preoperative Dynamic Contrast-Enhanced MRI Histogram Analysis in Patients with Glioblastoma: Analysis of Overall and Progression-Free Survival
  
    	
Y.S. Choi, D.W. Kim, S.-K. Lee, J.H. Chang, S.-G. Kang, E.H. Kim, S.H. Kim, T.H. Rim, S.S. Ahn

  
    	
American Journal of Neuroradiology Dec 2015, 36 (12) 2235-2241; DOI: 10.3174/ajnr.A4449 

  
  
  



  


  
  



  
      
  
  

    

  
    
  
  
    
  
  
    
  


  


  
  



  
      
  
  

    
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  


  
  



  



  


  
  



  
      
  
  

    
  


  
  



          

        

	
 	
	
	


  


  
  



  
      
  
  

    
              Purchase  


  
  



  
        
Jump to section

    
  
  

    
  


  
  



  
      
  
  

    
  


  
  



			

		

	
	
 	
	
	


    

  



  

                
    

      

  

    

  
      
  
  

    


Advertisement